Susan Burwig compensation by year
Medpace Summary Compensation Table · all 5 fiscal years held| Component | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Salary | $482,500 | $524,333 | $598,100 | $671,667 | $710,417 |
| Bonus | $338,800 | $367,000 | $418,880 | $352,700 | $497,400 |
| Stock awards | $0 | $206,460 | $0 | $3,770,000 | $0 |
| Option awards | $1,612,060 | $0 | — | $0 | $1,500,075 |
| Non-equity incentive | $0 | $112,946 | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | — | $0 | $0 |
| All other | $88,986 | $0 | $107,319 | $39,702 | $15,922 |
| Total | $2,522,346 | $1,210,739 | $1,124,299 | $4,834,069 | $2,723,814 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Medpace Holdings, Inc. DEF 14A filed April 1, 2026, accession 0001668397-26-000012, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 10,000 | $5,616,500 | — |
| RSU | 1,000 | $561,650 | — |
| Option | 34,060 | — | $138.87 |
| Option | 23,028 | — | $166.73 |
| Option | 10,984 | — | $107.93 |
| Option | 11,017 | — | $325.73 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Medpace Holdings, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
5 Form 4 lines since the FY2025 proxy (filed April 1, 2026)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-09-15 | Exercise or conversion | — | 3,000 | $166.73 | 65,984 |
| 2026-09-15 | Exercise or conversion derivative | — | 3,000 | $0.00 | 8,028 |
| 2026-07-28 | Sale | — | 7,500 | $600.00 | 62,984 |
| 2026-04-24 | Grant or award derivative | — | 5,000 | $0.00 | 5,000 |
| 2026-04-24 | Grant or award derivative | — | 10,000 | $0.00 | 10,000 |
The 5 most recent of 5 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Medpace’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| August Troendle | Chief Executive Officer and Chairman of the Board | $11,443,766 |
| Susan Burwig · this page | Executive Vice President, Operations | $2,723,814 |
| Jesse Geiger | President | $2,396,370 |
| Stephen Ewald | General Counsel and Corporate Secretary | $2,019,709 |
| Kevin Brady | Chief Financial Officer and Treasurer | $1,646,197 |
The full Medpace compensation record
free company briefThis page is one person within Medpace's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Medpace's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Medpace's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat